Get started
Author

Jing Li

ORCID: 0009-0000-4569-9933
Observed ORCID: 0009-0000-4569-9933
OpenAlex ID: A5092428754
Cholesterol metabolism in tumor immunity: Mechanisms and therapeutic opportunities for cancer
2025 · Xiao-jia Guo, Bo-bo Zhu, et al. · Biochemical Pharmacology · 29
State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy
2023 · Xin Zhong, Minling Lv, et al. · Biomedicine & Pharmacotherapy · 20
Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2024 · Seema Kantak, Raffaella Faggioni, et al. · Molecular Cancer Therapeutics · 9
PDF
Figure S5 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S4 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S2 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Data from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S6 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S8 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S1 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S3 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S9 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Supplementary Methods from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Table S1 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Figure S7 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Table S2 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
2025 · Seema Kantak, Raffaella Faggioni, et al.
Works count: 16
Citation count: 58
H-index: 3
I10-index: 2
Year
Topic
Type